期刊文献+

布地奈德/福莫特罗干粉吸入剂和喘可治联合治疗儿童支气管哮喘的临床研究 被引量:16

Clinical study on treatment of bronchial asthma in children with combination therapy of budesonide/foradil powder for inhalation and Chuankezhi
暂未订购
导出
摘要 目的评估布地奈德/福莫特罗干粉吸入剂和喘可治注射液联合治疗儿童支气管哮喘(轻度持续—中度持续)的临床疗效、依从性和安全性。方法采用随机、开放、平行对照研究方法,将64例患儿分为A组(布地奈德/福莫特罗干粉吸入剂组)37例和B组(布地奈德/福莫特罗干粉吸入剂+喘可治联合治疗组)27例,观察临床症状评分、视觉近似评价量尺(VAS量尺)、儿童哮喘控制测试(ACTCH)、最大呼气峰流速(PEF占预计值%)、肺功能(FEV1占预计值%)和不良事件发生情况。结果A、B两组药物治疗都可改善患儿的临床症状,但B组改善更明显(P<0.05);PEF占预计值%和FEV1占预计值%方面,两组都有改善,B组在治疗后4周改善PEF占预计值%快于A组(P<0.05),在治疗后4周、8周、12周改善FEV1占预计值%也优于A组(P<0.05),两组无明显不良事件发生。结论布地奈德/福莫特罗干粉吸入治疗和布地奈德/福莫特罗干粉吸入剂+喘可治联合治疗儿童支气管哮喘(轻度持续—中度持续)都具有良好的疗效和安全性,依从性好,但布地奈德/福莫特罗干粉吸入剂+喘可治联合治疗改善病情更快,疗效更好。 Objective To evaluate the clinical efficacy, compliance and safety of the combination therapy of budesonide/foradil powder for inhalation and Chuankezhi in the treatment of bronchial asthma in children (mild to moderate persistent). Methods In this open, randomized, parallel control study, 64 patients were divided into group A (budesonide/foradil powder for inhalation group) of 37 patients and group B (combination of budesonide/foradil powder for inhalation and Chuankezhi group) of 27 patients. Clinical symptom scale, visual analog scale (VAS), children asthma control test (ACTCH) , peak expiratory flow (PEF predictive value % ), lung function (FEV1 predictive value % ) and adverse-events were observed. Results The clinical symptoms were improved in both groups, but was more significant (P 〈 0.05) in group B. PEF predictive value % and FEV1 predictive value % was also improved in both groups. The improvement of PEF predictive value % in group B was faster than in group A after treatment for 4 weeks (P 〈 0.05). After treatment for 4 weeks, 8 weeks, and 12 weeks, the improvement of FEV1 predictive value % in group B were better than in group A (P 〈 0.05). No adverse-events were observed in both groups. Conclusions The budesonide/foradil powder for inhalation group (A) and the combination of budesonide/foradil powder for inhalation and Chuankezhi group (B) both have good clinical efficacy, compliance and safety, but the latter provides more rapid improvement and better efficacy than the former.
出处 《临床儿科杂志》 CAS CSCD 北大核心 2009年第7期682-685,共4页 Journal of Clinical Pediatrics
关键词 布地奈德/福莫特罗干粉吸入剂 喘可治 支气管哮喘 疗效 依从性 安全性 budesonide/fradil powder for inhalation Chuankezhi bronchial asthma efficacy compliance security
  • 相关文献

参考文献12

二级参考文献12

  • 1全国儿科哮喘协作组.全国90万0-14岁儿童中支气管哮喘患病情况调查[J].中华结核和呼吸杂志,1993,16:64-68.
  • 2Salome CM, Reddel HK, Ware SI, et al.Effect of budesonide on the perception of induced airway narrowing in subjects with asthma.Am J Respir Crit Care Med, 2002, 165: 15- 21.
  • 3Kalayci O, Saraclar Y, Adaliolu G, et al.The effect of cetirizine on sulfidoleukotriene production by blood leukocytes in children with allergic rhinitis.Allergy, 1995, 50: 964-969.
  • 4Tang M.IL- 4 and IFN-γ in children with atopic disease.Clin Exp Immunol, 1993, 92: 120- 135.
  • 5Moverare R, Elfinan L, Stalenheim G, et al.Study of the Th1/Th2 balance, including IL- 10 production in cultures of peripheral blood mononuclear cells from birch pollen allergic patients.Allergy, 2000, 55: 171- 175.
  • 6戴家熊,彭宜君,主编小儿变态(过敏)性疾病.第1版.上海:同济大学出版社,1991.100-102.
  • 7李明华,殷凯生,董竞成,主编.哮喘病药物治疗学.第1版.北京:人民卫生出版社,2003.
  • 8胡国让,沈自尹,施赛珠,陈伟华,涂灏,黄杰.血清IgE检测在评价补肾法防治支气管哮喘疗效中的应用[J]中医杂志,1982(05).
  • 9沈自尹,施赛珠,查良伦,胡国让,陈素珍,陈伟华,周杏仙.支气管哮喘采用补肾法防治及其内分泌和免疫方面的观察[J]中医杂志,1981(05).
  • 10儿童哮喘防治常规(试行)[J].中华儿科杂志,1998,36(12):747-751. 被引量:2368

共引文献3628

同被引文献161

引证文献16

二级引证文献36

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部